ClinicalTrials.gg
CompletedNCT05174312FASTRUpdated Jun 23, 2026Results posted

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

An interventional study of Reprieve Decongestion Management System and Diuretic in Acute Decompensated Heart Failure, sponsored by Reprieve Cardiovascular, Inc. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Reprieve Cardiovascular, Inc · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Enrollment
647th of 1,602
100 · median 66
Started
2022
with 106 others
No phase
887 of 2,159
159 open now
Registered
1,642nd of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 647th largest by enrollment of the 1,602 interventional ones that give a count, is one of 107 that started in 2022, is one of 887 with no phase, and was the 1,642nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more efficiently decongest ADHF patients in comparison to Control Therapy.

03

Conditions studied

  • Acute Decompensated Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hospitalized with a diagnosis of heart failure as defined by the presence of at least 1 symptom AND 1 sign.
  2. ≥10 pounds (4.5 kg) above dry weight either by historical weights or as estimated by health care provider.
  3. Prior use of loop diuretics within 30 says prior to admission.
  4. ≥ 18 years of age able to provide and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Inability to place Foley catheter or IV catheter.
  2. Hemodynamic instability.
  3. Dyspnea due primarily to non-cardiac causes.
  4. Acute infection with evidence of systemic involvement.
  5. Estimated (eGFR) \< 20 ml/min/1.73m2 calculated using the MDRD equation or current use of renal replacement therapy.
  6. Significant left ventricular outflow obstruction, uncorrected complex congenital heart disease, severe stenotic valvular disease, infiltrative or constrictive cardiomyopathy, acute myocarditis, type 1 acute myocardial infarction requiring treatment, or any other pathology that, in the opinion of the investigator, would make aggressive diuresis poorly tolerated.
  7. Inability to follow instructions or comply with follow-up procedures.
  8. Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures.
  9. Severe electrolyte abnormalities.
  10. Presence of active coronavirus disease 2019 (COVID-19) infection.
  11. Enrollment in another interventional trial during the index hospitalization.
  12. Inability to return for follow-up study visits.
  13. less than 3 months.
  14. Women who are pregnant or intend to become pregnant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Reprieve Decongestion Management System

    Subjects randomized to Reprieve System will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.

    Device: Reprieve Decongestion Management System

  • Active comparator
    Optimal Diuretic Therapy

    Sites will consider best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC) for patients randomized to control arm of the trial.

    Drug: Diuretic

Interventions

  • DeviceReprieve Decongestion Management System

    The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.

  • DrugDiureticsStudies of DiureticsDiuretics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).

06

What researchers measure

Primary outcomes

  1. Total Urine Sodium Output

    Primary efficacy endpoint is total urine sodium output at 24 hours post-treatment initiation.

    Time frame: 24 hours post-treatment initiation

  2. Clinically Significant Acute Kidney Injury, Severe Electrolyte Abnormality, Symptomatic Hypotension or Hypertensive Emergency.

    Primary safety endpoint includes clinically significant acute kidney injury defined as KDIGO stage 2 or greater AKI \[≥ doubling of baseline serum creatinine or use of renal replacement therapy (RRT)\], severe electrolyte abnormality (serum potassium \<3.0 mEq/L, magnesium \<1.3 mEq/L or sodium \<125 mEq), symptomatic hypotension or hypertensive emergency.

    Time frame: End of treatment, 0-72 hours.

Secondary outcomes

  1. Net Fluid Loss

    Difference in the amount of net fluid removed during primary treatment

    Time frame: End of treatment, 0-72 hours

  2. Time on IV Loop Diuretics

    Time from initiation of IV loop diuretics to discontinuation of IV loop diuretics

    Time frame: 0 hours (treatment initiation) through hospital discharge, up to 1-2 weeks

07

Results

Posted May 29, 2026

Participant flow

2,216 patients were screened between July 2022 and October 2024 at 16 hospitals in the United States.

Participant flow — Overall Study
MilestoneReprieve Decongestion Management SystemOptimal Diuretic Therapy
Started5644
Completed5244
Not completed40
Withdrew: Unable to pass urinary catheter40

Outcome measures

PrimaryTotal Urine Sodium Output

Primary efficacy endpoint is total urine sodium output at 24 hours post-treatment initiation.

Time frame:
24 hours post-treatment initiation
Reported as:
Mean · mmol of sodium
Total Urine Sodium Output
mmol of sodiumReprieve Decongestion Management SystemOptimal Diuretic Therapy
Total Urine Sodium Output1082 ± 487423 ± 290
Statistical analysis
  • Reprieve Decongestion Management System vs Optimal Diuretic Therapy · t-test, 2 sided · p = <0.001
PrimaryClinically Significant Acute Kidney Injury, Severe Electrolyte Abnormality, Symptomatic Hypotension or Hypertensive Emergency.

Primary safety endpoint includes clinically significant acute kidney injury defined as KDIGO stage 2 or greater AKI \[≥ doubling of baseline serum creatinine or use of renal replacement therapy (RRT)\], severe electrolyte abnormality (serum potassium \<3.0 mEq/L, magnesium \<1.3 mEq/L or sodium \<125 mEq), symptomatic hypotension or hypertensive emergency.

Time frame:
End of treatment, 0-72 hours.
Reported as:
Number · total number of events
Clinically Significant Acute Kidney Injury, Severe Electrolyte Abnormality, Symptomatic Hypotension or Hypertensive Emergency.
total number of eventsReprieve Decongestion Management SystemOptimal Diuretic Therapy
Clinically Significant Acute Kidney Injury, Severe Electrolyte Abnormality, Symptomatic Hypotension or Hypertensive Emergency.1619
Statistical analysis
  • Reprieve Decongestion Management System vs Optimal Diuretic Therapy · t-test, 2 sided · p = 0.43
SecondaryNet Fluid Loss

Difference in the amount of net fluid removed during primary treatment

Time frame:
End of treatment, 0-72 hours
Reported as:
Mean · liters
Net Fluid Loss
litersReprieve Decongestion Management SystemOptimal Diuretic Therapy
Net Fluid Loss8.1 ± 5.78.1 ± 7.1
SecondaryTime on IV Loop Diuretics

Time from initiation of IV loop diuretics to discontinuation of IV loop diuretics

Time frame:
0 hours (treatment initiation) through hospital discharge, up to 1-2 weeks
Reported as:
Median · hours
Time on IV Loop Diuretics
hoursReprieve Decongestion Management SystemOptimal Diuretic Therapy
Time on IV Loop Diuretics46 (29 to 80)88 (44 to 143)

Adverse events

Collected over From enrollment until end of follow up, up to 90 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reprieve Decongestion Management System3/52 (5.8%)29/52 (55.8%)44/52 (84.6%)
Optimal Diuretic Therapy3/44 (6.8%)23/44 (52.3%)35/44 (79.5%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventReprieve Decongestion Management SystemOptimal Diuretic Therapy
Cardiac disorderCardiac disorders17/5215/44
Infectious disordersInfections and infestations10/527/44
Renal and urinary disordersRenal and urinary disorders6/528/44
Metabolism and nutrition disordersMetabolism and nutrition disorders5/526/44
Vascular disordersVascular disorders6/524/44
Administration site disordersSkin and subcutaneous tissue disorders2/524/44
Respiratory, thoracic, and mediastinal disordersRespiratory, thoracic and mediastinal disorders2/524/44
Falls and limb injury disordersInjury, poisoning and procedural complications3/520/44
Psychiatric disordersPsychiatric disorders0/522/44
Nervous system disordersNervous system disorders2/521/44
Most frequent other events
Showing 10 of 14
Most frequent other events
EventReprieve Decongestion Management SystemOptimal Diuretic Therapy
Electrolyte and fluid disordersGeneral disorders27/5219/44
Renal and urinary disordersRenal and urinary disorders6/527/44
Vascular disorderVascular disorders5/521/44
Cardiac disorderCardiac disorders1/524/44
Electrolyte disorderGeneral disorders3/520/44
Other disordersGeneral disorders2/522/44
Catheter-associated UTIInfections and infestations1/522/44
Psychiatric disordersPsychiatric disorders0/521/44
Musculoskeletal disorderMusculoskeletal and connective tissue disorders1/521/44
Administration site disordersGeneral disorders1/520/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)Reprieve Decongestion Management SystemOptimal Diuretic TherapyTotal
Mean64 ± 1363 ± 1463 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)Reprieve Decongestion Management SystemOptimal Diuretic TherapyTotal
Female232043
Male292453
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Reprieve Decongestion Management SystemOptimal Diuretic TherapyTotal
White312657
Black181836
Other303
Serum creatinine
Serum creatinine(mg/dL)Reprieve Decongestion Management SystemOptimal Diuretic TherapyTotal
Mean1.48 ± 0.561.44 ± 0.561.46 ± 0.62
08

Study locations

16 sites
  • Eastern Shore Research Institute
    Fairhope, Alabama 36532, United States
  • University of California Irvine
    Irvine, California 92697, United States
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • Trinity Health Ann Arbor Hospital
    Ypsilanti, Michigan 48197, United States
  • St. Louis VA
    St Louis, Missouri 63130, United States
  • Washington University
    St Louis, Missouri 63130, United States
  • Duke University Hospital
    Durham, North Carolina 27710, United States
  • Cone Health
    Greensboro, North Carolina 27401, United States
  • Atrium Health Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • The Lindner Research Center at Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Ohio State University Hospital
    Columbus, Ohio 43210, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Prisma Health
    Columbia, South Carolina 29203, United States
  • Ascension Texas Cardiovascular
    Austin, Texas 78705, United States
  • Baylor Scott & White
    Dallas, Texas 75246, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
09

References and documents

Publications

  • Udelson JE, Javaheri A, Fudim M, Damman K, Biegus J, Afzal A, Amin AN, Bensimhon D, Bischof JJ, Chung ES, Gottlieb RL, Mahler SA, Moreno JD, Ponikowski P, Rao V, Cox Z, Ivey-Miranda J, Collins S, Testani J. Fluid Management of Acute Heart Failure With the Reprieve System: The Randomized Controlled FASTR Trial. JACC Heart Fail. 2026 Apr 28:103062. doi: 10.1016/j.jchf.2026.103062. Online ahead of print. PubMed 42068320 ↗
  • Cox ZL, Damman K, Testani JM. Decongestion in heart failure: medical and device therapies. Nat Rev Cardiol. 2025 Dec;22(12):961-977. doi: 10.1038/s41569-025-01152-z. Epub 2025 Apr 28. PubMed 40295876 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jan 2025, 29 months.

Results were first posted in May 2026, 1 year 4 months after primary completion.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 29 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Dec 30, 2021
StartActual
Jul 11, 2022
Primary completionActual
Jan 10, 2025
CompletionActual
Jan 10, 2025
Results first posted
May 29, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05174312
Lead sponsor
Reprieve Cardiovascular, Inc
Responsible party
Sponsor
First posted
Dec 30, 2021
Start date
Jul 11, 2022
Primary completion
Jan 10, 2025
Completion
Jan 10, 2025
Results posted
May 29, 2026
Last update
Jun 23, 2026

Study contacts

James E. Udelson, MD
principal investigator · Division of Cardiology and the CardioVascular Center, Tufts Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion